 Home > Medical News > Medical Research Articles > NRG Oncology Non-Small Cell Lung Cancer Trial has completed Phase 2 and data analysis is in progress to determine the restart of Phase 3

NRG Oncology Non-Small Cell Lung Cancer Trial has completed Phase 2 and data analysis is in progress to determine the restart of Phase 3

 Last Update: 2022-01-02
 Source: Internet
 Author: User

Tags

2 4 label

plica fimbriata cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The NRG oncology clinical trial NRG-lu002 compares local consolidation therapy (LCT) and maintenance system therapy for localized metastatic non-small cell lung cancer (NSCLC) with maintenance system therapy alone, and has recently reached the level of the study's Phase II trial.

The Phase 2 study of NRG-LU002 accumulates patients with limited metastatic NSCLC who have completed at least 4 cycles of first-line systemic therapy and have no signs of progression, and divide the patients into squamous or non-squamous disease stratification, and previous systemic treatment options

"Although maintenance system therapy has shown a significant improvement in the survival outcome of patients with metastatic NSCLC, the improvement of local control by local therapy may further stabilize the disease and prolong the life of patients with limited metastasis after initial treatment

If the trial restarts, the question of the third phase of the study will examine whether adding LCT to maintenance system therapy can improve the overall survival of patients with limited metastatic NSCLC

"NRG Oncology expresses its gratitude to the National Clinical Trial Network sites and researchers for their diligent work during the pandemic to accumulate patients for this trial.

NRG Oncology will send an e-mail broadcast when the decision to reopen the proceeds of the NRG-lu002 Phase III research question is made

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Neopentyl Glycol CAS NO.126-30-7 99% High Quality Factory Supply

CAS No.: 126-30-7

Industrial Grade

$1.7-2/KG FOB

Factory Supply Tirzepatide 10 mg 15mg Weight Loss Peptide 10mg 99.9% CAS: 2023788-19-2

CAS No.: 2023788-19-2

Pharmacy Grade

$4-5/UNIT FOB

good quality 2cb wholesale

CAS No.: 58743-75-2

$2-2.2/MT EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.